[在耐火性多发性骨髓瘤患者接受维护血液透析的Elranatamab治疗]
Yuki Nagahama1, Asuka Kono1, Yasumasa Nakata1
1Department of Hematology, Institute of Science Tokyo Hospital.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|February 1, 2026
概括
双特异性抗体Elranatamab在接受血液透析的患者中显示出治疗多发性骨髓瘤的前景. 这项案例研究强调了其安全性和有效性,即使在患有晚期疾病和并发症的患者中也是如此.
科学领域:
- 血液学 血液学 血液学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- 多发性骨髓瘤是一种血液性恶性瘤,通常与脏并发症有关,例如需要血液透析的造脏病.
- 治疗耐药性和外骨髓性疾病进展是治疗多发性骨髓瘤的重大挑战,特别是在末期病患者中.
- 关于新型双特异性抗体在接受血液透析的多发性骨髓瘤患者中使用的数据有限.
研究的目的:
- 评估elranatamab在患有复发性/耐药性多发性骨髓瘤和需要血液透析的末期病的患者的安全性和有效性.
- 评估这种具有挑战性的患者群体中对elranatamab的耐受性和临床反应.
主要方法:
- 一个单臂病例研究68岁男性多发性骨髓瘤和血液透析依赖的急性损伤.
- 在非透析日开始用elranatamab治疗时,使用标准前期药物治疗,而不需要调整剂量.
- 监测不良事件,包括细胞因子释放综合征和免疫效应细胞相关的神经毒性综合征. 通过PET/CT扫描评估的临床反应.
主要成果:
- 埃拉拉纳塔马布耐受性良好,只有1级细胞因子释放综合征,没有观察到神经毒性.
- 经过4次ELRANATAMAB治疗周期后,PET/CT显示出额外骨髓质量显著回归.
- 患者在8个周期内实现了持续的临床反应,没有显著的不良事件.
结论:
- 埃拉拉纳塔马布可以安全有效地给患有多发性骨髓瘤的患者服用,需要进行血液透析.
- 埃拉拉纳塔马布代表了对患有末期脏病多发性骨髓瘤患者的可行和有前途的治疗选择.
- 对这种患者群体的双特异性抗体进行进一步的研究是有必要的.
相关概念视频
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
238
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
238
01:25Hemodialysis I: Introduction
1.7K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
1.7K
01:24Hemodialysis II: Procedure and Complications
821
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
821
01:25Hemodialysis III: Nursing Management
884
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
884
01:49Multiple Allele Traits
38.1K
The Concept of Multiple Allelism
38.1K
01:14Maintenance of the ES Cell State
2.8K
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
2.8K